339 related articles for article (PubMed ID: 31640747)
1. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM
Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747
[TBL] [Abstract][Full Text] [Related]
2. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
4. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
6. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
7. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
8. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
9. The Potential of PSMA as a Vascular Target in TNBC.
Heesch A; Ortmanns L; Maurer J; Stickeler E; Sahnoun SEM; Mottaghy FM; Morgenroth A
Cells; 2023 Feb; 12(4):. PubMed ID: 36831218
[TBL] [Abstract][Full Text] [Related]
10. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF
J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652
[TBL] [Abstract][Full Text] [Related]
11. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
12. Value of post-therapy
Tuncel M; Telli T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750
[TBL] [Abstract][Full Text] [Related]
13. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
14. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
15. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [
Heesch A; Florea A; Maurer J; Habib P; Werth LS; Hansen T; Stickeler E; Sahnoun SEM; Mottaghy FM; Morgenroth A
Breast Cancer Res; 2024 Feb; 26(1):30. PubMed ID: 38378689
[TBL] [Abstract][Full Text] [Related]
16. [PSMA-targeted radioligand therapy in prostate cancer].
Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
[TBL] [Abstract][Full Text] [Related]
17. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
Kryza D; Vinceneux A; Bidaux AS; Garin G; Tatu D; Cropet C; Badel JN; Perol D; Giraudet AL
BMC Cancer; 2024 Feb; 24(1):163. PubMed ID: 38302933
[TBL] [Abstract][Full Text] [Related]
18. Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.
Nguyen DP; Xiong PL; Liu H; Pan S; Leconet W; Navarro V; Guo M; Moy J; Kim S; Ramirez-Fort MK; Batra JS; Bander NH
Mol Cancer Res; 2016 Nov; 14(11):1045-1053. PubMed ID: 27458033
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
[TBL] [Abstract][Full Text] [Related]
20. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
